Integrating Pretreatment Circulating Tumor HPV DNA and Tumor Volume for Risk Stratification in HPV-Positive Oropharyngeal Squamous Cell Carcinoma
Open Access
Abstract
Background: Circulating tumor HPV DNA (ctHPV DNA) has shown clinical value in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), but its relationship with tumor burden and its role in prognosis, especially when combined with clinicoradiological factors, remain to be further defined. Methods: We analyzed 103 patients with HPV-positive OPSCC enrolled in an observational biomarker study, most of whom received induction chemotherapy or chemoimmunotherapy followed by definitive radiotherapy. Blood samples were collected at pretreatment, post-radiotherapy, and follow-up time points, and ctHPV DNA levels were quantified using droplet digital PCR. Baseline clinicoradiological parameters from contrast-enhanced MR or CT and 18F-FDG PET/CT were analyzed for their association with ctHPV DNA levels and clinical outcomes. Results: Baseline ctHPV DNA correlated with primary tumor volume (VT), nodal volume (VN), total tumor volume (VT+N), and the number of involved primary tumor sites and lymph node regions, particularly LN-related features. VT and maximum LN diameter were independent predictors of baseline ctHPV DNA. Detectable follow-up ctHPV DNA was associated with inferior progression-free survival but showed low sensitivity and positive predictive value for relapse detection. Integrative stratification using baseline ctHPV DNA and VT+N identified a potential high-risk subgroup with high tumor volume but paradoxically low ctHPV DNA (VOLhighDNAlow). Exploratory RNA-seq analysis was performed to investigate potential biological features underlying this discordance, and a seven-gene signature associated with PFS was identified. Conclusions: These findings suggest that baseline ctHPV DNA reflects tumor burden and may provide additional information for upfront risk stratification in HPV-positive OPSCC, warranting further validation in larger prospective cohorts.Keywords
Funding Information
- National Natural Science Foundation of China (32201014)
- Shanghai Clinical Research Center (21MC1930300)
This publication has 41 references indexed in Scilit:
- Postoperative ctHPVDNA Kinetics in Patients With HPV-Related Oropharyngeal CancerJAMA Otolaryngology–Head & Neck Surgery, 2025
- Circulating Tumor Tissue‐Modified‐Viral HPV DNA and Correlations With Disease Burden in Oropharyngeal CancerOtolaryngology–Head and Neck Surgery, 2025
- Pretreatment Liquid Biopsy and Clinicopathologic Features in HPV−Associated Oropharyngeal Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2025
- Whole genome sequencing-powered ctDNA sequencing for breast cancer detectionAnnals of Oncology, 2025
- Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignanciesAnnals of Oncology, 2024
- Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancerAnnals of Oncology, 2023
- Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus–Associated Oropharyngeal CancerJAMA Otolaryngology–Head & Neck Surgery, 2023
- Association of Pretreatment Circulating Tumor Tissue–Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal CancerJAMA Otolaryngology–Head & Neck Surgery, 2022
- HPV circulating tumoral DNA quantification by droplet‐based digital PCR: A promising predictive and prognostic biomarker for HPV‐associated oropharyngeal cancersInternational Journal of Cancer, 2019
- Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancerCancer, 2015